Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Alkermes price target raised to $33 from $29 at Mizuho » 06:34
07/29/21
07/29
06:34
07/29/21
06:34
ALKS

Alkermes

$25.76 /

+1.63 (+6.76%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan raised the firm's price target on Alkermes to $33 from $29 and reiterates a Buy rating on the shares. The company reported better than expected Q2 results, as sales for key products exceeded consensus expectations, Divan tells investors in a research note. Both Vivitrol and Aristada beat expectations, Vumerity is starting to gain traction, and Alkermes will be launching Lybalvi next quarter, says the analyst. Divan believes the company is now executing well, both commercially and on the development side, and sees "multiple potential drivers of further upside."

ShowHide Related Items >><<
ALKS Alkermes
$25.76 /

+1.63 (+6.76%)

ALKS Alkermes
$25.76 /

+1.63 (+6.76%)

07/06/21 Mizuho
Alkermes shares should continue to run, says Mizuho
06/07/21 Mizuho
Alkermes oncology asset underappreciated by investors, says Mizuho
06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
ALKS Alkermes
$25.76 /

+1.63 (+6.76%)

ALKS Alkermes
$25.76 /

+1.63 (+6.76%)

ALKS Alkermes
$25.76 /

+1.63 (+6.76%)

Wednesday
Earnings
Alkermes raises FY21 non-GAAP EPS to 52c-70c from 37c-62c, consensus 51c » 07:21
07/28/21
07/28
07:21
07/28/21
07:21
ALKS

Alkermes

$24.12 /

-0.25 (-1.03%)

Raises FY21 revenue view…

Raises FY21 revenue view to $1.15B-$1.19B from $1.10B-$1.17B, consensus $1.14B.

ShowHide Related Items >><<
ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

07/06/21 Mizuho
Alkermes shares should continue to run, says Mizuho
06/07/21 Mizuho
Alkermes oncology asset underappreciated by investors, says Mizuho
06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

Earnings
Alkermes reports Q2 non-GAAP EPS 30c, consensus 12c » 07:19
07/28/21
07/28
07:19
07/28/21
07:19
ALKS

Alkermes

$24.12 /

-0.25 (-1.03%)

Reports Q2 revenue…

Reports Q2 revenue $303.7M, consensus $278.7M. "Alkermes' strong performance in the second quarter was driven by commercial execution and our focus on profitability. Vivitrol and Aristada demonstrated robust sequential and year-over-year growth and Vumerity continued on an encouraging launch trajectory," commented CFO Iain Brown. "Today, we are raising our financial expectations for full-year 2021 to reflect this performance and anticipated continued strength in the business. We believe that we are in a sound financial position to execute on our business strategy and efficiently invest in our future potential growth drivers."

ShowHide Related Items >><<
ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

07/06/21 Mizuho
Alkermes shares should continue to run, says Mizuho
06/07/21 Mizuho
Alkermes oncology asset underappreciated by investors, says Mizuho
06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

ALKS Alkermes
$24.12 /

-0.25 (-1.03%)

Over a week ago
Recommendations
Alkermes shares should continue to run, says Mizuho » 06:41
07/06/21
07/06
06:41
07/06/21
06:41
ALKS

Alkermes

$25.29 /

+0.385 (+1.55%)

After meeting with…

After meeting with management, Mizuho analyst Vamil Divan says shares of Alkermes (ALKS) should continue to run. Management remains very encouraged by the data they are seeing from nemvaleukin, both in monotherapy and in combination with Merck's (MRK) Keytruda, Divan tells investors in a research note. Beyond nemvaleukin, the analyst has sensed increasing investor interest in the Alkermes story in recent months. With the Lybalvi approval now in hand, the focus is on how well the company will be able to commercialize the product, says Divan. The analyst keeps a Buy rating on Alkermes with a $29 price target.

ShowHide Related Items >><<
ALKS Alkermes
$25.29 /

+0.385 (+1.55%)

ALKS Alkermes
$25.29 /

+0.385 (+1.55%)

06/07/21 Mizuho
Alkermes oncology asset underappreciated by investors, says Mizuho
06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
04/29/21 H.C. Wainwright
Alkermes price target raised to $24 from $23 at H.C. Wainwright
ALKS Alkermes
$25.29 /

+0.385 (+1.55%)

ALKS Alkermes
$25.29 /

+0.385 (+1.55%)

ALKS Alkermes
$25.29 /

+0.385 (+1.55%)

Over a month ago
Conference/Events
Alkermes participates in a conference call with Mizuho » 04:55
06/18/21
06/18
04:55
06/18/21
04:55
ALKS

Alkermes

$24.68 /

-0.4 (-1.60%)

Conference call with…

Conference call with management will be held on June 18 hosted by Mizuho.

ShowHide Related Items >><<
ALKS Alkermes
$24.68 /

-0.4 (-1.60%)

ALKS Alkermes
$24.68 /

-0.4 (-1.60%)

06/07/21 Mizuho
Alkermes oncology asset underappreciated by investors, says Mizuho
06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
04/29/21 H.C. Wainwright
Alkermes price target raised to $24 from $23 at H.C. Wainwright
ALKS Alkermes
$24.68 /

-0.4 (-1.60%)

ALKS Alkermes
$24.68 /

-0.4 (-1.60%)

ALKS Alkermes
$24.68 /

-0.4 (-1.60%)

Conference/Events
Alkermes participates in a conference call with Mizuho » 13:52
06/14/21
06/14
13:52
06/14/21
13:52
ALKS

Alkermes

$24.71 /

-0.305 (-1.22%)

Conference call with…

Conference call with management will be held on June 18 hosted by Mizuho.

ShowHide Related Items >><<
ALKS Alkermes
$24.71 /

-0.305 (-1.22%)

ALKS Alkermes
$24.71 /

-0.305 (-1.22%)

06/07/21 Mizuho
Alkermes oncology asset underappreciated by investors, says Mizuho
06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
04/29/21 H.C. Wainwright
Alkermes price target raised to $24 from $23 at H.C. Wainwright
ALKS Alkermes
$24.71 /

-0.305 (-1.22%)

ALKS Alkermes
$24.71 /

-0.305 (-1.22%)

ALKS Alkermes
$24.71 /

-0.305 (-1.22%)

Recommendations
Alkermes oncology asset underappreciated by investors, says Mizuho » 07:13
06/07/21
06/07
07:13
06/07/21
07:13
ALKS

Alkermes

$23.07 /

+ (+0.00%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan reiterates a Buy rating on Alkermes with a $29 price target after the company released additional data for its pipeline oncology asset nemvaleukin alfa. The data show continued progress for the product both as monotherapy and in combination with Merck's Keytruda, and with both an intravenous and subcutaneous formulation, Divan tells investors in a research note. The analyst believes investors are underappreciating nemvaleukin and the opportunity for "significant value creation" in the near-term as the product moves through registrational trials and Alkermes likely signs a "valuable collaboration agreement with a larger biopharma partner."

ShowHide Related Items >><<
ALKS Alkermes
$23.07 /

+ (+0.00%)

ALKS Alkermes
$23.07 /

+ (+0.00%)

06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
04/29/21 H.C. Wainwright
Alkermes price target raised to $24 from $23 at H.C. Wainwright
04/26/21 Mizuho
Alkermes price target raised to $29 from $28 at Mizuho
ALKS Alkermes
$23.07 /

+ (+0.00%)

ALKS Alkermes
$23.07 /

+ (+0.00%)

ALKS Alkermes
$23.07 /

+ (+0.00%)

Conference/Events
Alkermes to host conference call » 15:55
06/04/21
06/04
15:55
06/04/21
15:55
ALKS

Alkermes

$23.07 /

+ (+0.00%)

Management, along with an…

Management, along with an expert oncologist panel, discusses data on Nemvaleukin Alfa presented at the 2021 ASCO Annual Meeting on a conference call to be held on June 4 at 4 pm. Webcast Link

ShowHide Related Items >><<
ALKS Alkermes
$23.07 /

+ (+0.00%)

ALKS Alkermes
$23.07 /

+ (+0.00%)

06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
04/29/21 H.C. Wainwright
Alkermes price target raised to $24 from $23 at H.C. Wainwright
04/26/21 Mizuho
Alkermes price target raised to $29 from $28 at Mizuho
ALKS Alkermes
$23.07 /

+ (+0.00%)

ALKS Alkermes
$23.07 /

+ (+0.00%)

ALKS Alkermes
$23.07 /

+ (+0.00%)

Hot Stocks
Alkermes announces new data from ARTISTRY program for nemvaleukin alfa » 09:20
06/04/21
06/04
09:20
06/04/21
09:20
ALKS

Alkermes

$23.07 /

-0.245 (-1.05%)

Alkermes announced new…

Alkermes announced new data from its ARTISTRY clinical development program for nemvaleukin alfa, Alkermes' novel, investigational engineered interleukin-2 variant immunotherapy. The data are being presented at the 2021 American Society of Clinical Oncology Annual Meeting, taking place virtually June 4-8, and in an investor webcast presentation hosted by the company. The presentations include updated efficacy and safety data from ARTISTRY-1, an ongoing phase 1/2 study investigating intravenous nemvaleukin, which showed anti-tumor activity of IV nemvaleukin monotherapy in checkpoint inhibitor-experienced melanoma and renal cell carcinoma patients, and anti-tumor activity of IV nemvaleukin in combination with pembrolizumab in a range of difficult-to-treat tumors, including in CPI-unapproved tumor types, and in CPI-approved tumor types among both CPI treatment-naive and pretreated patients. Durable and deepening responses have been observed with IV nemvaleukin, as monotherapy or in combination with pembrolizumab, in platinum-resistant ovarian cancer and mucosal melanoma. Treatment-related adverse events were mostly transient and manageable and the maximum tolerated dose had not yet been reached. Alkermes' presentations also include data from ARTISTRY-2, an ongoing phase 1/2 study evaluating subcutaneous nemvaleukin. Findings include a pharmacodynamic response and safety profile that support the recommended phase 2 dose, and encouraging early signs of anti-tumor activity in PROC.

ShowHide Related Items >><<
ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
04/29/21 H.C. Wainwright
Alkermes price target raised to $24 from $23 at H.C. Wainwright
04/26/21 Mizuho
Alkermes price target raised to $29 from $28 at Mizuho
ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

Conference/Events
Alkermes to host conference call » 04:55
06/04/21
06/04
04:55
06/04/21
04:55
ALKS

Alkermes

$23.07 /

-0.245 (-1.05%)

Management, along with an…

Management, along with an expert oncologist panel, discusses data on Nemvaleukin Alfa presented at the 2021 ASCO Annual Meeting on a conference call to be held on June 4 at 4 pm. Webcast Link

ShowHide Related Items >><<
ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
06/01/21 Goldman Sachs
Goldman keeps Sell on Alkermes, says Lybalvi not 'practice changing'
04/29/21 H.C. Wainwright
Alkermes price target raised to $24 from $23 at H.C. Wainwright
04/26/21 Mizuho
Alkermes price target raised to $29 from $28 at Mizuho
ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

ALKS Alkermes
$23.07 /

-0.245 (-1.05%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.